• Company Type For Profit
  • Contact Email mail@scaledbiolabs.com
  • Phone Number +114156551868

Scaled Biolabs is pioneering a Cell Therapy Discovery Engine, working at the frontier of microfluidics, automation, and machine learning to develop best-in-class cell-based medicines. This engine enables leading biotech and pharma companies to survey hundreds of parameters across tens of thousands of experimental processes, providing an

unprecedented window into cell-driven biology. This enables the development of novel and optimal cell-based products and processes, simplifying manufacturing, reducing time to market, and improving clinical outcomes. Scaled Biolabs also develops cell therapy assets internally, including a CIRM-funded program focusing on iPSC-derived dopaminergic neurons as a curative cell therapy for Parkinson’s disease.

Lists Featuring This Company

Biotechnology Seed Stage Companies With Less Than $10M in Revenue
1,791 Number of Organizations • $6.2B Total Funding Amount • 5,308 Number of Investors
San Francisco Bay Area Seed Stage Companies With Less Than $1M in Revenue
1,532 Number of Organizations • $1.6B Total Funding Amount • 4,053 Number of Investors
California Companies With Less Than $1M in Revenue (Top 10K)
9,954 Number of Organizations • $50.2B Total Funding Amount • 15,258 Number of Investors
San Francisco Seed Stage Companies
4,140 Number of Organizations • $10.5B Total Funding Amount • 14,841 Number of Investors

Frequently Asked Questions

Where is Scaled Biolabs's headquarters? Scaled Biolabs is located in San Francisco, California, United States.Who invested in Scaled Biolabs? Scaled Biolabs has 3 investors including SOSV and IndieBio.How much funding has Scaled Biolabs raised to date? Scaled Biolabs has raised .When was the last funding round for Scaled Biolabs? Scaled Biolabs closed its last funding round on Oct 11, 2017 from a Seed round.Who are Scaled Biolabs's competitors? Alternatives and possible competitors to Scaled Biolabs may include METiS TherapeuticsKytopen, and Rainier Therapeutics.